Patrick S. Gagnon
Education
Master’s, economics, University of Quebec in Montreal; baccalaureate, economics, Laval University
Summary of Experience
Mr. Gagnon is an economist who specializes in applying advanced econometric methods to health economics and outcomes research (HEOR), with a particular focus in database analyses. He has participated in the development and implementation of data analytics throughout the product life cycle, from pre-marketing to post-marketing real-world evidence (RWE) generation. His areas of expertise include economic burden assessment, health economic modeling, predictive analytics, and stakeholder submissions. Mr. Gagnon has conducted analyses for pharmaceutical companies in a variety of therapeutic areas, including cirrhosis, irritable bowel syndrome, opioid-induced constipation, macular edema, scleroderma, sickle cell disease, Alzheimer’s disease, post-traumatic stress disorder, attention deficit hyperactivity disorder, major depressive disorder, bipolar disorder, and oncology. His work has been used to inform reimbursement decisions in the US and has been presented at numerous conferences and published in multiple peer-reviewed journals, such as The Journal of Clinical Psychiatry, the Journal of Managed Care & Specialty Pharmacy, BMC Psychiatry, BMJ Open Ophthalmology, and PLOS One.
-
Treatment Patterns among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis
Advances in Therapy, 2023
2023Schein J, Childress A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Cloutier M, Guérin A
-
Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning Approach
BMC Psychiatry, 2022
2022Gagnon-Sanschagrin P, Schein J, Urganis A, Serra E, Liang Y, Musingarimi P, Cloutier M, Guérin A, Davis L
-
Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysis
BMC Psychiatry, 2022
2022Schein J, Childress A, Adams J, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A
-
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective
Journal of Medical Economics, 2022
2022Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P
-
The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective
The Journal of Clinical Psychiatry, 2022
2022Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle CR
-
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective
Journal of Managed Care & Specialty Pharmacy, 2022
2022Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P
-
Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department
Advances in Therapy, 2022
2022Peacock WF, Slatkin N, Gagnon-Sanschagrin P, Maitland J, Guérin A, Joseph G
-
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study
Current Medical Research and Opinion, 2021
2021Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, Guérin A, Lefebvre P
-
Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage
Journal of Medical Economics, 2021
2021Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, Guérin A, Cloutier M
-
Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspective
BMJ Open Opthalmology, 2021
2021Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, Serra E, Bhattacharyya S, Bédard J, Guérin A, Albini TA
-
Impact of agitation in long-term care residents with dementia in the United States
International Journal of Geriatric Psychiatry, 2021
2021Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G
-
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers
Journal of Medical Economics, 2020
2020Shah NR, Bhor M, Latremouille-Viau D, Sharma VK, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Singh MK, Serra E, Davidson M, Xu L, Guerin A
-
The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis
Journal of Managed Care & Specialty Pharmacy, 2019
2019Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ
-
Institutionalization risk and costs associated with agitation in Alzheimer's disease
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019
2019Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Aigbogun MS
-
Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer
Advances in Therapy. 2018 Sep;35(9):1356-1367
2018Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guérin A, Niravath P, Small T
-
Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
Advances in Therapy. Mar 20 2018
2018Gauthier G, Gagnon-Sanschagrin P, Guérin A, Burne R, Small T, Niravath P, Dalal AA
-
Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. April 13, 2018
2018Dalal AA, Gagnon-Sanschagrin P, Burne R, Guérin A, Gauthier G, Small T, Niravath P
-
Assessment of costs associated with adverse events in patients with cancer
PloS One. 2018;13(4):e0196007
2018Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A
-
Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
Advances in Therapy, 2018 Oct;35(10):1671-1685
2018Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ
-
Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis
J Drugs Dermatol. Feb 1 2018;17(2):180-186
2018Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A
-
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. 2018 Aug;35(8):1251-1264
2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA
-
A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States
Journal of Medical Economics. 2018 Dec;21(12):1183-1190
2018Cloutier M, Greene M, Touya M, Gagnon-Sanschagrin P, Guérin A
-
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
Journal of Medical Economics. 2018 Jun;21(6):556-563
2018Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ
-
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis
Journal of Drugs in Dermatology, 2018
2018Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A
-
Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency
Journal of Managed Care and Specialty Pharmacy. 2017;23(2):214-224
2017Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ
-
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.
-
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia(1)
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L
-
May 8, 2023
-
October 23, 2023
-
June 27, 2023
-
March 22, 2023
-
October 17, 2022
-
April 13, 2021